Valneva announces positive lot-to-lot consistency trial results for its single-shot chikungunya vaccine candidate

Saint herblain ( france), december 21 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced positive topline results from the lot-to-lot phase 3 trial of its single-shot chikungunya vaccine candidate, vla1553. the vla1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer gmt ratios on day 29 after vaccination.
VALN Ratings Summary
VALN Quant Ranking